News
This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company
In a sure sign that the biotech bull market is alive and well, Rhythm Pharmaceuticals (NASDAQ: RYTM) raised almost $120 million at $17 per share in its initial public offering on Thursday. In its....
Healthcare: Are These the Best Dividend Stocks to Buy Now?
Demand in the healthcare sector isn't tied as closely to the state of the economy as it is in most other sectors. Because of that, dividend-paying healthcare stocks may offer income investors some....
Here's Why AnaptysBio Inc. Is Rocketing Higher Today
Shares of AnaptysBio Inc. (NASDAQ: ANAB), a clinical-stage biotech developing novel anti-inflammatory drugs, took flight after the company reported positive data from a clinical trial with its....
Why CRISPR Therapeutics AG Stock Lost Ground in September
According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) dropped by 13.1% in September. CRISPR's poor showing last month....
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ: CELG) have quadrupled since 2007. Biogen Inc. (NASDAQ:....
Why the Bears Are Wrong About Keryx Biopharmaceuticals Stock
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters, it's not even a biotech company (trying for the old "bait-and-switch" move, eh?). It doesn't....
3 Healthcare Dividend Stocks Ideal for Retirees
What does an ideal investment portfolio look like for retirees? The answer to that question varies based on each individual's financial position and goals. However, nearly every retiree wants to....
3 Monster Stocks in the Making
Halloween is right around the corner, which makes it the perfect time to look for monster stocks in the making. What are some characteristics these stocks might have? Leading market positions,....
$50,000 Per Year in Prescription Drugs? You Likely Know Someone Who Used at Least That Much
For most Americans, $50,000 is a lot of money. Six out of 10 households in the U.S. have make less than that amount per year (based on adjusted gross income). But, for a growing number of....
2 Stocks Your Children Will Brag About Someday
While few and far between, some businesses are so strong that they can create wealth for generations. That's why we Fools think it's a worthwhile endeavor to constantly search the markets for....
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) continued its monster climb this year with a 10% gain in September, according to data from S&P Global Market Intelligence. Preclinical results....
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
Shares of NewLink Genetics (NASDAQ: NLNK), a small-cap clinical-stage drug developer focused on therapies to treat cancer, skyrocketed by 25% in September, according to data from S&P Global....
3 Stocks That Could Lose You a Lot of Money
Even the most successful investors swing and miss from time to time. It's a big, messy world out there, and no one has all the information they need to scout out only winning stocks for their....
Roundtable: 1 Stock Retirees Should Consider
Time magazine declares that "70 is the new 50." And just because you're retired doesn't mean it's time to stop investing. In fact, retirement may be the best time to invest in stocks. Seriously,....
What's Behind AstraZeneca's September Rebound?
After a tough couple of months, British pharma giant AstraZeneca (NYSE: AZN) actually saw its shares rise by a healthy 12.5% last month, according to data from S&P Global Market Intelligence.....
3 High-Yield Healthcare Stocks
Picking solid high-yield dividend stocks can be tricky. Most companies that offer an elevated yield, after all, tend to do so because of a fundamental weakness in their underlying business. Our....
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin just might be the most controversial topic in the investing world. Supporters think the cryptocurrency has the potential to disrupt the financial industry. They also point to bitcoin's....
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
"Dividend Aristocrat" just has a nice ring to it, doesn't it? The "dividend" part sounds great because it means a stock is going to pay you to own it. "Aristocrat" conveys nobility, an elite....
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
3 Drug Stocks That Soared This Week: Are They Buys?
Most investors would be quite happy to get a 20% return over the course of a year. Of course "happy" wouldn't begin to describe the feeling of getting an even better return than that in just a....
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way,....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors....